Shopping Cart
- Remove All
Your shopping cart is currently empty
BVFP
Catalog No. T79105Cas No. 357158-20-4
BVFP exhibits affinity for the PGRN 588–593 peptide through binding with a dissociation constant (Kd) of 20 μM and is capable of disrupting the interaction between PGRN and SORT1. Moreover, BVFP inhibits the SORT1-mediated endocytosis of recombinant PGRN (rPGRN) [1].
BVFP
Catalog No. T79105Cas No. 357158-20-4
BVFP exhibits affinity for the PGRN 588–593 peptide through binding with a dissociation constant (Kd) of 20 μM and is capable of disrupting the interaction between PGRN and SORT1. Moreover, BVFP inhibits the SORT1-mediated endocytosis of recombinant PGRN (rPGRN) [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | 8-10 weeks | |
| 50 mg | Inquiry | 8-10 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BVFP"
(±)-AC 7954 hydrochloride
T22476477313-09-0
(±)-AC 7954 hydrochloride is a urotensin-II (UT) receptor activator.
- $82
Size
QTY
SB-657510
T12848474960-44-6
SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models.
- $75
Size
QTY
SB 611812
T23323345892-71-9
SB 611812 is an antagonist of urotensin-II (UT) and can be used in studies about the treatment of cardiovascular disease.
- $38
Size
QTY
[Lys8, Lys9]-Neurotensin (8-13) acetate
T38807L
[Lys8, Lys9]-Neurotensin (8-13) acetate, a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively[1].
- $89
Size
QTY
AF38469
AF-38469
TQ00861531634-31-7
AF38469 is a new, specific and orally bioavailable Sortilin inhibitor (IC50: 330 nM).
- $107
Size
QTY
Substance P 1-9 aceate
TP1819L
Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.
- $59
Size
QTY
Urantide acetate(669089-53-6 free base)
TP2106L
Urantide acetate is a selective and competitive urotensin-II (UT) receptor antagonist (pKB = 8.3). Blocks hU-II induced contractions in thoracic aorta ex vivo. Exhibits no effect on noradrenaline or endothelin 1-induced contraction or on acetylcholine-ind
- $115
Size
QTY
Neurotensin
TP131039379-15-2
Neurotensin is a 13 amino acid neuropeptide that is implicated in the regulation of luteinizing hormone and prolactin release and has significant interaction with the dopaminergic system.
- $52
Size
QTY
Kinetensin acetate(103131-69-7 free base)
Kinetensin (human) acetate
TP1116L
Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.
- $96
Size
QTY
Neurotensin(8-13) 3TFA(60482-95-3(free base))
T7617L2952825-79-3
Neurotensin(8-13) 3TFA is Neurotensin (NT) fragment. Neurotensin(8-13) 3TFA results in a decrease in cell-surface NT1 receptors (NTR1) density.
- $32
Size
QTY
SORT-PGRN interaction inhibitor 1
T9044100957-85-5
SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction, with an IC50 of 2 μM.
- $29
Size
QTY
SBI-553
Cited
T168601849603-72-0
SBI-553 is an effective and brain penetrant NTR1 allosteric modulator (EC50: 0.34 μM).
- $97
Size
QTY
CitedContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | BVFP exhibits affinity for the PGRN 588–593 peptide through binding with a dissociation constant (Kd) of 20 μM and is capable of disrupting the interaction between PGRN and SORT1. Moreover, BVFP inhibits the SORT1-mediated endocytosis of recombinant PGRN (rPGRN) [1]. |
| Molecular Weight | 345.11 |
| Formula | C13H8BrF3N2O |
| Cas No. | 357158-20-4 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BVFP | purchase BVFP | BVFP cost | order BVFP | BVFP chemical structure | BVFP formula | BVFP molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.